BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 21812901)

  • 21. Association of serum lipid levels and prostate cancer severity among Hispanic Puerto Rican men.
    Salgado-Montilla J; Soto Salgado M; Surillo Trautmann B; Sánchez-Ortiz R; Irizarry-Ramírez M
    Lipids Health Dis; 2015 Sep; 14():111. PubMed ID: 26377420
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of obesity on the diagnosis of prostate cancer using a modern extended biopsy scheme.
    Pruthi RS; Swords K; Schultz H; Carson CC; Wallen EM
    J Urol; 2009 Feb; 181(2):574-7; discussion 578. PubMed ID: 19084847
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of ageing and body mass index on prostate-specific antigen levels among Chinese men in Singapore from a community-based study.
    Chia SE; Lau WK; Chin CM; Tan J; Ho SH; Lee J; Cheng C
    BJU Int; 2009 Jun; 103(11):1487-91. PubMed ID: 19076145
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Obesity does not correlate with adverse pathologic findings on transperineal template-guided mapping biopsy of the prostate.
    Bittner N; Merrick GS; Stewart R; Andreini H; Taubenslag W; Curtis R; Butler WM; Wallner KE
    Urol Oncol; 2011; 29(4):398-404. PubMed ID: 19945303
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lowering the PSA threshold for prostate biopsy from 4 to 2.5 ng/ml: influence on cancer characteristics and number of men needed to biopt.
    Müntener M; Kunz U; Eichler K; Puhan M; Schmid DM; Sulser T; Strebel RT
    Urol Int; 2010; 84(2):141-6. PubMed ID: 20215816
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and pathologic predictors of Gleason sum upgrading in patients after radical prostatectomy: results from a single institution series.
    Tilki D; Schlenker B; John M; Buchner A; Stanislaus P; Gratzke C; Karl A; Tan GY; Ergün S; Tewari AK; Stief CG; Seitz M; Reich O
    Urol Oncol; 2011; 29(5):508-14. PubMed ID: 19837614
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Body mass index and prostate-specific antigen failure following brachytherapy for localized prostate cancer.
    Efstathiou JA; Skowronski RY; Coen JJ; Grocela JA; Hirsch AE; Zietman AL
    Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1302-8. PubMed ID: 18262732
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
    Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
    J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
    Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
    Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk factors of positive surgical margin and biochemical recurrence of patients treated with radical prostatectomy: a single-center 10-year report.
    Li K; Li H; Yang Y; Ian LH; Pun WH; Ho SF
    Chin Med J (Engl); 2011 Apr; 124(7):1001-5. PubMed ID: 21542957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediagnostic prostate-specific antigen velocity and probability of detecting high-grade prostate cancer.
    Krejcarek SC; Chen MH; Renshaw AA; Loffredo M; Sussman B; D'Amico AV
    Urology; 2007 Mar; 69(3):515-9. PubMed ID: 17382156
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of diabetes mellitus on the detection of prostate cancer via contemporary multi (≥ 12)-core prostate biopsy.
    Hong SK; Oh JJ; Byun SS; Hwang SI; Lee HJ; Choe G; Lee SE
    Prostate; 2012 Jan; 72(1):51-7. PubMed ID: 21520162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association between serum prostate-specific antigen level, liver function tests and lipid profile in healthy men.
    Han JH; Chang IH; Ahn SH; Kwon OJ; Bang SH; Choi NY; Park SW; Myung SC; Kim HW
    BJU Int; 2008 Nov; 102(9):1097-101. PubMed ID: 18522630
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
    Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
    BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary Gleason grade 4 impact on biochemical recurrence after permanent interstitial brachytherapy in Japanese patients with low- or intermediate-risk prostate cancer.
    Uesugi T; Saika T; Edamura K; Nose H; Kobuke M; Ebara S; Abarzua F; Katayama N; Yanai H; Nasu Y; Kumon H
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e219-23. PubMed ID: 21640517
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Staging of prostate cancer: value of the combined information of endorectal MRI, biopsy Gleason score, and preoperative PSA level].
    Wetter A; Ajdukovic AN; Fliessbach K; Lehnert T; Engl T; Jacobi V; Vogl TJ
    Rofo; 2006 Apr; 178(4):385-90. PubMed ID: 16607587
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Relationship between serum prostate-specific antigen levels and body mass index in Beijing men over 50 years of age].
    Wang Y; Zhou Z; Tian Y; Shao Q; Chen S; Hong BF; Zhang XH; Ren XH; Sun WX; Wang ZW; Na YQ
    Zhonghua Yi Xue Za Zhi; 2009 Jun; 89(24):1681-3. PubMed ID: 19957525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolic syndrome increases the risk of aggressive prostate cancer detection.
    Morote J; Ropero J; Planas J; Bastarós JM; Delgado G; Placer J; Celma A; de Torres IM; Carles J; Reventós J; Doll A
    BJU Int; 2013 Jun; 111(7):1031-6. PubMed ID: 22883053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Type of diabetes mellitus and the odds of Gleason score 8 to 10 prostate cancer.
    Kang J; Chen MH; Zhang Y; Moran BJ; Dosoretz DE; Katin MJ; Braccioforte MH; Salenius SA; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e463-7. PubMed ID: 21944463
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.